title: The state-of-the-art in chemoprevention of skin cancer.
abstract: The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate. Our chemoprevention strategies include the development of novel agents evaluated by (1) preclinical mechanistic studies in models of ultraviolet (UV) radiation-induced skin carcinogenesis; (2) clinical studies of immunohistochemical surrogate endpoint biomarkers in high-risk patients; and (3) randomised, placebo-controlled phase I, II and III clinical chemoprevention trials. Recent clinical results validate this development model. Molecular targets of chemopreventive strategies for melanoma and non-melanoma skin cancers include the ras and activator protein-1 (AP-1) signal transduction pathways. A transgenic murine melanoma model has been developed for evaluating potential agents in vivo. Agents at various stages of study include the green tea catechin epigallocatechin gallate (EGCG), the limonene derivative perillyl alcohol, the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO), selenium, retinoids and salicylates. New chemopreventive agents that can be used to complement sunscreens may result in decreased incidence, morbidity and mortality of skin cancer.
authors.affiliation: Arizona Cancer Center, College of Medicine, University of Arizona, Tucson, AZ 85724, USA. stratton@azcc.arizona.edu
authors.forename: S P
authors.initials: SP
authors.lastname: Stratton
authors.forename: R T
authors.initials: RT
authors.lastname: Dorr
authors.forename: D S
authors.initials: DS
authors.lastname: Alberts
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D000518:Eflornithine / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000517:prevention & control*; D051379:Mice; D016032:Randomized Controlled Trials as Topic; D012643:Selenium / Q000627:therapeutic use; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D018808:Transcription Factor AP-1 / Q000187:drug effects; D014466:Ultraviolet Rays / Q000009:adverse effects*; D014801:Vitamin A / Q000627:therapeutic use
chemical_list: D018808:Transcription Factor AP-1; D014801:Vitamin A; D012643:Selenium; D000518:Eflornithine